Zydus and Lupin Partner to Co-Market Semaglutide Injection for Diabetes and Weight Management in India

Zydus Lifesciences and Lupin have entered a licensing and supply agreement to co-market semaglutide injections in India, aiming to expand access to treatments for type 2 diabetes and chronic weight management. Lupin will have semi-exclusive rights to market the drug under the brands Semanext and Livarise, while Zydus will sell it as Semaglyn, Mashema, and Alterme. The injection uses a reusable pen device designed for patient convenience. Lupin will pay licensing fees and milestone payments to Zydus. This collaboration leverages Zydus' development capabilities and Lupin's market reach ahead of the patent expiry of Novo Nordisk's semaglutide.